Tag: Anticoagulants

Two strong recommendations developed against use of heparin bridging in a-fib, and for continuation of VKA in patients getting pacemaker/ICD

However, no significant difference seen in efficacy or safety outcomes for clopidogrel versus no antiplatelet therapy

Risk for adverse health outcomes higher for patients with Medicare Part D plans limiting access to non-vitamin K antagonist oral anticoagulants

Guideline addresses management of anticoagulants, antiplatelets during acute gastrointestinal bleeding and in the elective endoscopy setting

Recent use of non-vitamin K antagonist oral anticoagulant not linked to increased risk for intracranial hemorrhage with IV alteplase

Direct oral anticoagulants reduce recurrent VTE events by 41 percent, with no significant increase in major bleeding, compared to dalteparin

Risks for diabetes complications, mortality lower with non-vitamin K antagonist oral anticoagulants versus warfarin

Almost all hospitalized COVID-19 patients with a bleeding event were receiving mechanical ventilation, full-dose anticoagulation

Adding a P2Y12 inhibitor to a therapeutic dose of heparin does not improve outcomes among non-critically ill patients hospitalized for COVID-19

Frail patients with nonvalvular atrial fibrillation also less likely to receive a direct oral anticoagulant versus warfarin